Eli Lilly announced study results for its oral obesity treatment, orforglipron, demonstrating its effectiveness in adults with both obesity and type 2 diabetes. The research, led by Professor Deborah Horn of the University of Texas Medical School, found that the drug led to a weight reduction of up to 10% over a 72-week period. In addition to weight loss, orforglipron was also found to lower blood glucose levels in these patients. While the weight-loss effect is noted to be less potent than existing injectable treatments, the convenience of an oral medication is expected to generate significant interest within the market. This development positions Lilly to further compete in the lucrative market for obesity and diabetes treatments with a more patient-friendly administration option.